IIQ Stock Overview
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
INOVIQ Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.55 |
| 52 Week High | AU$0.98 |
| 52 Week Low | AU$0.42 |
| Beta | 2.17 |
| 1 Month Change | -6.78% |
| 3 Month Change | 4.76% |
| 1 Year Change | 0% |
| 3 Year Change | -82.70% |
| 5 Year Change | -8.33% |
| Change since IPO | -16.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| IIQ | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | -12.7% | 2.2% | 0.9% |
| 1Y | 0% | -21.8% | 5.6% |
Return vs Industry: IIQ exceeded the Australian Healthcare industry which returned -21.8% over the past year.
Return vs Market: IIQ underperformed the Australian Market which returned 5.6% over the past year.
Price Volatility
| IIQ volatility | |
|---|---|
| IIQ Average Weekly Movement | 11.6% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IIQ's share price has been volatile over the past 3 months.
Volatility Over Time: IIQ's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | n/a | Leearne Hinch | www.inoviq.com |
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers.
INOVIQ Ltd Fundamentals Summary
| IIQ fundamental statistics | |
|---|---|
| Market cap | AU$49.23m |
| Earnings (TTM) | -AU$6.51m |
| Revenue (TTM) | AU$1.58m |
31.1x
P/S Ratio-7.6x
P/E RatioIs IIQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IIQ income statement (TTM) | |
|---|---|
| Revenue | AU$1.58m |
| Cost of Revenue | AU$3.26m |
| Gross Profit | -AU$1.68m |
| Other Expenses | AU$4.83m |
| Earnings | -AU$6.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.071 |
| Gross Margin | -105.79% |
| Net Profit Margin | -410.78% |
| Debt/Equity Ratio | 0% |
How did IIQ perform over the long term?
See historical performance and comparison